Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Somnomed Limited ( (AU:SOM) ) just unveiled an announcement.
SomnoMed Limited has released its 2025 Full Year Report, highlighting a significant 21.6% increase in revenue from ordinary activities to $111.5 million. Despite reporting a loss from ordinary activities after tax of $3.5 million, this marks a substantial improvement of 71.8% compared to the previous year. The company announced that no dividend will be paid for the year ended 30 June 2025, reflecting a strategic focus on reinvestment and growth. The results suggest a positive trajectory in financial performance, potentially enhancing SomnoMed’s positioning in the sleep-related breathing disorder treatment industry.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited is a public company specializing in treatment solutions for sleep-related breathing disorders such as obstructive sleep apnea, snoring, and bruxism. The company has commercialized its products based on extensive clinical research, supporting independent clinical research, continuous innovation, and medical manufacturing standards. Its flagship product, SomnoDent, is a state-of-the-art and clinically proven medical oral appliance therapy used by over 1 million patients in more than 20 countries.
Average Trading Volume: 65,479
Technical Sentiment Signal: Hold
Current Market Cap: A$159.3M
Find detailed analytics on SOM stock on TipRanks’ Stock Analysis page.